A Phase 3 interventional study of Recombinant nonimmunogenic staphylokinase and Alteplase in Massive Pulmonary Embolism, sponsored by Supergene, LLC. Completed at 23 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by Supergene, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Tissue Plasminogen Activator in Pulmonary Embolism — 1 open to participants now, 4 under way, 2 of them phase 3. Tissue Plasminogen Activator · Pulmonary Embolism.
Among the 15 studies testing Tissue Plasminogen Activator in Pulmonary Embolism, this one is the 4th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 3, and was the 14th registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →1 of the 15 studies testing Tissue Plasminogen Activator in Pulmonary Embolism is open now, in 1 country. Recruiting first, the newest first:
Thrombolex, Inc. · Sites in United States
By country, each count listing its studies:
Tissue Plasminogen Activator: first FDA approval 1987 (ACTIVASE). What it is approved for, and how studies give it, is on its page →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2020.
This study's enrollment of 310 is above the median of 174 across 430 interventional studies indexed under Pulmonary Embolism.
Median enrollment 118 across the 15 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 10 most frequent:
Supergene, LLC is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Supergene, LLC has 3 studies filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Tissue Plasminogen Activator in Pulmonary Embolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Objective: to evaluate the efficacy and safety of the Recombinant Non-immunogenic Staphylokinase with its single bolus administration in comparison with the bolus-infusion administration of the Alteplase in patients with massive pulmonary embolism
The main goal of treating massive PE is to save the lives of patients by restoring pulmonary perfusion, preventing the development of chronic postembolic pulmonary hypertension and recurrent PE. According to data of clinical trials, with timely initiation of therapy for massive pulmonary embolism, mortality can be significantly reduced.
Recombinant protein which contains aminoacid sequence of staphylokinase - Fortelizin® (the active substance is Forteplase). It is single chain molecula, consists of 138 aminoacids, weight 15.5 kDa. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. This complex activates plasminogen trapped in the thrombus. The plasmin-staphylokinase complex and plasmin bound to fibrin are protected from inhibition by alpha2-antiplasmin. Once liberated from the clot (or generated in plasma), however, they are rapidly inhibited by alpha2-antiplasmin. This selectivity of action confines the process of plasminogen activation to the thrombus, preventing excessive plasmin generation, alpha2-antiplasmin depletion, and fibrinogen degradation in plasma. In rabbits anti forteplase antibodies are not produced. It was achieved by replacement of amino acids in immunogenic epitop of molecule staphylokinase. Blood fibrinogen decrease after i.v. injection of Fortelyzin less 10% within first 24 hours. Angiographic data suggests that restoration of coronary blood flow appears in up to 80% of patients with STEMI after i.v. injection of Fortelyzin.
The main objectives of the study: to assess the efficacy, safety and possible adverse events of the drug Recombinant Non-immunogenic Staphylokinase with its single bolus administration in comparison with the bolus-infusion administration of the drug Alteplase® in patients with massive pulmonary embolism.
Study Design. Multicenter, open-label, randomized, comparative clinical study of non-inferiority study of efficacy and safety in parallel groups. At clinical centers, patients will be equally randomly distributed by the "envelope" method into two groups of 155 patients each (310 people in total, including 10% of those who may have dropped out)to receive Recombinant Non-immunogenic Staphylokinase or Alteplase®.
The drugs will be administered after the signed informed consent. Recombinant Non-immunogenic Staphylokinase will be administered intravenously at a dose of 15 mg as a single bolus for 10-15 seconds. Alteplase® will be administered in accordance with the instructions for use.
Patients will be monitored for 30 days from the moment of randomization: in the intensive care unit up to 7 days, after it in the hospital until discharge - an average of 14 days and an outpatient visits on the 30th day. The recruitment of patients for the study will be competitive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient consent to use reliable methods throughout the study and for 3 weeks after:
Exclusion Criteria:
Increased risk of bleeding:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.
Drug: Recombinant nonimmunogenic staphylokinase
Alteplase® is administered in accordance with the instructions for use for pulmonary embolism( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
Drug: Alteplase
15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
Also known as: Fortelyzin
Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
Also known as: Actillyze
Death From All Causes
The efficacy is evaluated in terms of the number of deaths from all causes
Time frame: within 7 days
Systolic Pulmonary Artery Pressure Measures (V1, V2, V4, V5)
The efficacy is evaluated in terms of systolic pulmonary artery pressure values
Time frame: baseline and day 1, 7, 14 after randomisation
Haemodynamic Collapse
The efficacy is evaluated in terms of the number of haemodynamic collapse
Time frame: within 7 days
Recurrent Pulmonary Embolism (PE)
The efficacy is evaluated in terms of the number of recurrent PE
Time frame: within 7 days
Death From PE
The efficacy is evaluated in terms of the number of deaths from PE
Time frame: within 30 days
Death From All Causes
The efficacy is evaluated in terms of the number of deaths from all causes
Time frame: within 30 days
Haemodynamic Collapse Within 7 Days + Recurrent PE Within 7 Days + Death From All Causes Within 30 Days
The efficacy is evaluated in terms of the number of haemodynamic collapse + recurrent PE + deaths from all causes
Time frame: within 30 days
Safety Endpoint - Haemorrhagic Stroke
The safety is evaluated in terms of the number of haemorrhagic stroke within 7 days of randomisation
Time frame: within 7 days
Safety Endpoint - BARC Type 3+5 Bleeding
The safety is evaluated in terms of the number of BARC type 3+5 bleeding. Type 3a: overt bleeding plus a hemoglobin drop of 3 to 5 g/dL; any transfusion with overt bleeding. Type 3b: overt bleeding plus a hemoglobin drop of 5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring intravenous vasoactive agents. Type 3c: intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal); subcategories confirmed by autopsy or imaging, or lumbar puncture; intraocular bleed compromising vision. Type 5a: probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious. Type 5b: definite fatal bleeding; overt bleeding or autopsy, or imaging confirmation.
Time frame: within 30 days
Safety Endpoint - Number and Severity of Serious Adverse Events (SAEs)
The safety is evaluated in terms of the number and severity of serious adverse events (SAEs)
Time frame: within 30 days
| Milestone | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Started | 155 | 155 |
| Completed | 145 | 146 |
| Not completed | 10 | 9 |
The efficacy is evaluated in terms of the number of deaths from all causes
| Participants | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Death From All Causes | 3 | 4 |
The efficacy is evaluated in terms of systolic pulmonary artery pressure values
| mm Hg | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| PASP on baseline | 59 (50 to 69) | 58 (51 to 69) |
| PASP on day 1 | 44 (36 to 52) | 42 (36 to 50) |
| PASP on day 7 | 36 (31 to 44) | 35 (29 to 41) |
| PASP on day 14 | 35 (30 to 41) | 35 (28 to 41) |
The efficacy is evaluated in terms of the number of haemodynamic collapse
| events | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Haemodynamic Collapse | 1 | 3 |
The efficacy is evaluated in terms of the number of recurrent PE
| events | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Recurrent Pulmonary Embolism (PE) | 1 | 2 |
The efficacy is evaluated in terms of the number of deaths from PE
| Participants | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Death From PE | 4 | 2 |
The efficacy is evaluated in terms of the number of deaths from all causes
| Participants | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Death From All Causes | 6 | 4 |
The efficacy is evaluated in terms of the number of haemodynamic collapse + recurrent PE + deaths from all causes
| events | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Haemodynamic Collapse Within 7 Days + Recurrent PE Within 7 Days + Death From All Causes Within 30 Days | 8 | 9 |
The safety is evaluated in terms of the number of haemorrhagic stroke within 7 days of randomisation
| events | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Safety Endpoint - Haemorrhagic Stroke | 0 | 3 |
The safety is evaluated in terms of the number of BARC type 3+5 bleeding. Type 3a: overt bleeding plus a hemoglobin drop of 3 to 5 g/dL; any transfusion with overt bleeding. Type 3b: overt bleeding plus a hemoglobin drop of 5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring intravenous vasoactive agents. Type 3c: intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal); subcategories confirmed by autopsy or imaging, or lumbar puncture; intraocular bleed compromising vision. Type 5a: probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious. Type 5b: definite fatal bleeding; overt bleeding or autopsy, or imaging confirmation.
| events | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Safety Endpoint - BARC Type 3+5 Bleeding | 0 | 5 |
The safety is evaluated in terms of the number and severity of serious adverse events (SAEs)
| events | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Safety Endpoint - Number and Severity of Serious Adverse Events (SAEs) | 9 | 17 |
Collected over 30 days.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Recombinant Nonimmunogenic Staphylokinase | 6/145 (4.1%) | 9/145 (6.2%) | 72/155 (46.5%) |
| Alteplase | 4/146 (2.7%) | 17/146 (11.6%) | 86/155 (55.5%) |
| Event | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| Death from all causesCardiac disorders | 6/145 | 4/146 |
| Haemodynamic collapseCardiac disorders | 1/145 | 3/146 |
| Haemorrhagic strokeNervous system disorders | 0/145 | 3/146 |
| Recurrent PECardiac disorders | 1/145 | 2/146 |
| Cerebral oedemaNervous system disorders | 0/145 | 2/146 |
| Ischaemic strokeNervous system disorders | 1/145 | 0/146 |
| Brainstem damageNervous system disorders | 0/145 | 1/146 |
| Haematoma of the thighCardiac disorders | 0/145 | 1/146 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 0/145 | 1/146 |
| Event | Recombinant Nonimmunogenic Staphylokinase | Alteplase |
|---|---|---|
| HematuriaBlood and lymphatic system disorders | 72/155 | 86/155 |
310 patients were randomly assigned to receive either non-immunogenic staphylokinase (n=155) or alteplase (n=155)
| Age, Categorical(Participants) | Recombinant Nonimmunogenic Staphylokinase | Alteplase | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 75 | 94 | 169 |
| >=65 years | 80 | 61 | 141 |
| Age, Continuous(years) | Recombinant Nonimmunogenic Staphylokinase | Alteplase | Total |
|---|---|---|---|
| Mean | 64 ± 13 | 62 ± 13 | 63 ± 13 |
| Sex: Female, Male(Participants) | Recombinant Nonimmunogenic Staphylokinase | Alteplase | Total |
|---|---|---|---|
| Female | 84 | 74 | 158 |
| Male | 71 | 81 | 152 |
| Race (NIH/OMB)(Participants) | Recombinant Nonimmunogenic Staphylokinase | Alteplase | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 155 | 155 | 310 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Recombinant Nonimmunogenic Staphylokinase | Alteplase | Total |
|---|---|---|---|
| Russia | 155 | 155 | 310 |
| Body mass index, kg/m^2(kg/m^2) | Recombinant Nonimmunogenic Staphylokinase | Alteplase | Total |
|---|---|---|---|
| Mean | 32 ± 6 | 31 ± 6 | 32 ± 6 |
| Pulmonary Embolism Severity Index (PESI) score(score) | Recombinant Nonimmunogenic Staphylokinase | Alteplase | Total |
|---|---|---|---|
| Median | 135 (116 to 150) | 128 (113 to 145) | 132 (115 to 147) |
| PESI class V patients(Participants) | Recombinant Nonimmunogenic Staphylokinase | Alteplase | Total |
|---|---|---|---|
| Count of participants | 103 | 82 | 185 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Jul 2023, 31 months.
Results were first posted in Apr 2025, 1 year 8 months after primary completion.
Of 31 phase 3 interventional studies under Pulmonary Embolism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: auR protein, Staphylococcus aureus · Tissue Plasminogen Activator
Supergene, LLC